Latest Insider Positions


Danziger Asaf is listed as an insider in the following companies: NVCR / NovoCure Limited Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
NVCR / NovoCure Chief Executive Officer, Director 70,113

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-07-06 NVCR / NovoCure A 795 70,113 1.15 17.255 13,718
2018-06-27 NVCR / NovoCure S -70,364 69,318 -50.37 32.086 -2,257,699 2,224,137 -101.51
2018-06-20 NVCR / NovoCure S -8,308 139,682 -5.61 32.0351 -266,148 4,474,727 -5.95
2018-06-19 NVCR / NovoCure S -621 147,990 -0.42 32.00 -19,872 4,735,680 -0.42
2018-06-18 NVCR / NovoCure S -22,289 148,611 -13.04 32.00 -713,248 4,755,552 -15.00
2018-06-14 NVCR / NovoCure S -200 170,900 -0.12 32.00 -6,400 5,468,800 -0.12
2018-06-13 NVCR / NovoCure S -11,720 171,100 -6.41 32.00 -375,040 5,475,200 -6.85
2018-06-04 NVCR / NovoCure S -2,800 182,820 -1.51 32.00 -89,600 5,850,240 -1.53
2018-06-04 NVCR / NovoCure S -19,694 185,620 -9.59 31.64 -623,118 5,873,017 -10.61
2018-06-04 NVCR / NovoCure S -28,150 205,314 -12.06 30.34 -854,071 6,229,227 -13.71
2018-06-04 NVCR / NovoCure S -26,782 233,464 -10.29 29.31 -784,980 6,842,830 -11.47
2018-06-04 NVCR / NovoCure S -149,878 260,246 -36.54 28.43 -4,261,032 7,398,794 -57.59
2018-02-22 NVCR / NovoCure M 53,334 410,124 14.95 21.55 1,149,348
2018-01-29 NVCR / NovoCure S -13,974 356,790 -3.77 24.0152 -335,588 8,568,383 -3.92
2018-01-25 NVCR / NovoCure S -6,456 370,764 -1.71 22.4349 -144,840 8,318,053 -1.74
2018-01-24 NVCR / NovoCure S -10,600 377,220 -2.73 22.1705 -235,007 8,363,156 -2.81
2018-01-23 NVCR / NovoCure S -10,248 387,820 -2.57 22.033 -225,794 8,544,838 -2.64
2018-01-16 NVCR / NovoCure S -14,900 398,068 -3.61 22.1983 -330,755 8,836,433 -3.74
2018-01-12 NVCR / NovoCure S -22,895 412,968 -5.25 22.0239 -504,237 9,095,166 -5.54
2018-01-11 NVCR / NovoCure S -313,525 435,863 -41.84 22.3507 -7,007,503 9,741,843 -71.93
2018-01-08 NVCR / NovoCure A 283 749,388 0.04 15.045 4,258
2017-11-06 NVCR / NovoCure S -6,919 749,105 -0.92 22.00 -152,218 16,480,310 -0.92
2017-11-03 NVCR / NovoCure S -2,300 756,024 -0.30 22.00 -50,600 16,632,528 -0.30
2017-11-01 NVCR / NovoCure S -15,716 758,324 -2.03 22.0075 -345,870 16,688,815 -2.07
2017-10-31 NVCR / NovoCure S -150 774,040 -0.02 22.00 -3,300 17,028,880 -0.02
2017-09-25 NVCR / NovoCure S -900 774,190 -0.12 22.05 -19,845 17,070,890 -0.12
2017-09-14 NVCR / NovoCure S -1,772 775,090 -0.23 22.00 -38,984 17,051,980 -0.23
2017-09-13 NVCR / NovoCure S -35,500 776,862 -4.37 22.0146 -781,518 17,102,306 -4.57
2017-07-14 NVCR / NovoCure M 354,780 812,362 77.53 0.38 134,816
2017-07-11 NVCR / NovoCure S -5,183 457,582 -1.12 20.19 -104,645 9,238,581 -1.13
2017-07-11 NVCR / NovoCure S -2,200 462,765 -0.47 19.40 -42,680 8,977,641 -0.48
2017-07-10 NVCR / NovoCure S -203,900 464,965 -30.48 18.077 -3,685,900 8,405,172 -43.85
2017-07-07 NVCR / NovoCure S -70,459 668,865 -9.53 18.034 -1,270,658 12,062,311 -10.53
2017-07-06 NVCR / NovoCure S -5,050 739,324 -0.68 18.088 -91,344 13,372,893 -0.68
2017-07-05 NVCR / NovoCure S -155,088 744,374 -17.24 18.144 -2,813,917 13,505,922 -20.83
2017-07-05 NVCR / NovoCure A 2,545 899,462 0.28 6.673 16,983
2017-06-19 NVCR / NovoCure S -124,720 896,917 -12.21 15.514 -1,934,906 13,914,770 -13.91
2017-06-16 NVCR / NovoCure S -9,212 1,021,637 -0.89 15.018 -138,346 15,342,944 -0.90
2017-06-15 NVCR / NovoCure S -33,245 1,030,849 -3.12 15.187 -504,892 15,655,504 -3.23
2017-06-14 NVCR / NovoCure S -5,402 1,064,094 -0.51 15.007 -81,068 15,968,859 -0.51
2017-06-13 NVCR / NovoCure S -88,700 1,069,496 -7.66 15.232 -1,351,078 16,290,563 -8.29
2017-06-12 NVCR / NovoCure S -5,100 1,158,196 -0.44 15.085 -76,934 17,471,387 -0.44
2017-06-09 NVCR / NovoCure S -175,501 1,163,296 -13.11 15.128 -2,654,979 17,598,342 -15.09
2017-02-27 NVCR / NovoCure M 342,954 1,338,797 34.44 0.17 58,302
2017-01-06 NVCR / NovoCure A 3,156 995,843 0.32 6.673 21,060
2016-04-13 NVCR / NovoCure M 59,130 992,687 6.33 0.17 10,052
2016-03-03 NVCR / NovoCure P 10,000 933,557 1.08 15.00 150,000 14,003,355 1.07
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of Danziger Asaf include the following: Ambrogi Michael J., Burkoth William T., DOYLE WILLIAM F, FUTRELL STEVE, GRANOFF MICHAEL D, GROENHUYSEN WILHELMUS CM, HILLEMAN JERYL L, Hung David, JANIS FRANCES, Kirson Eilon D., LAVIGNE LOUIS J JR, LEUNG GABRIEL, Langloss Timothy J., Longsworth Todd Christopher, MYLOD ROBERT J JR, Madden Martin J., McCoy Sherilyn S, Melnyk Peter M., PHILLIPS CHARLES G III, Palti Yoram, Perlhagen Gert L., Pomona Associates VII, L.P., Pomona Capital VII Fund Investors, L.P., Pomona Capital VII, L.P., Pomona G.P. Holdings LLC, Pomona Secondary Associates VII LLC, Shah Pritesh, VERNON W ANTHONY, Volati Ltd, WFD Ventures Fund II, L.P., Wyss Hansjoerg, . Peers are determined by cross-linking the filings of Danziger Asaf with insider filings of others at the same companies.

Related News Stories

3 Medical Devices Stocks to Buy

2018-10-02 investorplace
When you think of medical devices stocks, you don’t think of cloud-connected watches. You want to invest in more prosaic companies, large and small, which offer discrete devices for specific conditions, with Food and Drug Administration (FDA) approvals and positive clinical trials. (0-1)

Under Armour Has Bottomed - Cramer's Lightning Round (10/1/18)

2018-10-02 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, October 1. (31-0)

Verastem Declines On Its Much-Touted Catalyst, Is It Worth Buying Now?

2018-09-26 seekingalpha
Verastem had its ups and downs in 2018, but they've finally gotten their first drug approval in non-Hodgkin lymphoma. (45-2)

Investing In The 'Softer Side' Of Biotech, Without Getting Emotional

2018-09-18 seekingalpha
Biotechs have been a bit bumpy lately due to lack of anticipated M&A action, with record outflows from some of the sector's largest ETFs, including XBI and IBB. (61-0)

Week In Review: $1.4 Billion In China Life Science Deals And Financings

2018-09-17 seekingalpha
Vivo Capital, a US-China healthcare investment firm, closed a new private equity fund at an oversubscribed $635 million. The Vivo Opportunity Fund will invest in the US and China small to mid-cap public life sciences companies with novel products in development. Vivo raised $750 million for its previous PE fund in 2015, and it closed a $100 million venture capital fund in 2016. The firm, which has offices in Palo Alto, Beijing, Shanghai and Taipei, now has $2.